ALK and non-small cell lung carcinoma: Multiple mechanisms of crizotinib resistance have been described in ALK-positive NSCLC, with secondary mutations in the ALK kinase domain having been detected in approximately 20% of patients, most commonly L1196 M (the “gate-keeper” mutation) and G1269A [4–6].